Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Lineage Cell Therapeutics (NYSE: LCTX) has announced a registered direct offering of up to $66 million through the sale of 39,473,688 common shares and warrants. The offering includes $30 million upfront ($24 million from institutional investors and $6 million from Broadwood Partners) at $0.76 per share-warrant combination. Additional proceeds of up to $36 million may come from warrant exercises at $0.91 per share. The warrants are exercisable after six months and expire within three years or 90 days after OpRegen's Phase 2/3 trial announcement. The offering to institutional investors should close around November 21, 2024, while Broadwood's portion requires shareholder approval.

Lineage Cell Therapeutics (LCTX) reported Q3 2024 financial results with revenues of $3.8 million, up from $1.2 million in Q3 2023. The company posted a net loss of $3.0 million ($0.02 per share), improved from $7.1 million loss year-over-year. Operating expenses decreased to $7.6 million from $7.9 million. Cash position of $32.7 million is expected to fund operations into Q1 2026.

Key highlights include OpRegen receiving RMAT designation from FDA, continued collaboration with Roche/Genentech, and presentation of ReSonance preclinical results at the Inner Ear Biology Workshop.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 or through the company's website. A replay will be available online for 30 days and by phone until November 21, 2024, using conference ID 2238934.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, has announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The company's CEO, Brian M. Culley, will be featured in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.

The fireside chat is scheduled for Tuesday, October 15, 2024, at 11:00 a.m. ET. It will be available for viewing by registered conference attendees. This event provides an opportunity for Lineage Cell Therapeutics to showcase its progress and discuss its innovative approach to addressing unmet medical needs through allogeneic cell therapies.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium. Culley will participate in a panel on "Clinical Trial Updates: PSC-Derived Therapies of the Eye" on October 2nd, 2024. The symposium, held from October 2-4, 2024, focuses on PSC-Derived Cell Therapies.

The presentation will feature OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells being developed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OpRegen is currently in a Phase 2a clinical study and is being developed in collaboration with Roche and Genentech. The presentation will be available on Lineage's website after the panel.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) presented preclinical results for ReSonance (ANP1), its auditory neuronal cell transplant for hearing loss treatment, at the 59th Annual Inner Ear Biology Workshop. Key highlights include:

1. ReSonance is manufactured using a proprietary in-house process at clinical scale.
2. The product showed relevant in-vitro functional activity and durable engraftment in multiple preclinical hearing loss models.
3. ReSonance is formulated as an immediate-use, thaw-and-inject product.
4. The company successfully advanced from concept to preclinical testing, generating new intellectual property.

Lineage CEO Brian Culley emphasized the company's manufacturing capabilities as a competitive advantage in the cell transplant space.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Brian M. Culley, the company's CEO, will be presenting at the event. The presentation will be available for on-demand viewing starting at 7:00am ET on the day of the conference for registered attendees.

Interested parties can also access a replay of the presentation on the Events and Presentations section of Lineage's website. The company specializes in developing allogeneic cell therapies for unmet medical needs, particularly in the field of ophthalmology. Additional videos showcasing Lineage's work are available on the Media page of their website.

Lineage Cell Therapeutics reported its second quarter 2024 financial results, marking significant developments and collaborations. The company highlighted the ongoing Phase 2a study of OpRegen® for geographic atrophy in partnership with Roche and Genentech, showcasing positive 24-month visual acuity data. They initiated services under a new agreement with Genentech, and continued preparations for the OPC1 spinal cord injury clinical study.

Financially, Lineage posted a net loss of $5.8 million, or $0.03 per share, with revenues dropping to $1.4 million from $3.2 million YoY. Operating expenses decreased to $7.3 million, driven by lower R&D expenses. The company held $38.5 million in cash and equivalents, expected to fund operations into Q4 2025.

Key events included clinical data presentations, the 2nd Annual Spinal Cord Injury Investor Symposium, and continued inclusion in the Russell 3000® Index.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies, has announced its plans to report second quarter 2024 financial and operating results on August 8, 2024, after the U.S. financial markets close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide a business update.

Interested parties can access the call by dialing (800) 715-9871 from the U.S. and Canada, requesting the "Lineage Cell Therapeutics Call". A live webcast will be available in the Investors section of Lineage's website. A replay of the webcast will be accessible on the company's website for 30 days, and a telephone replay will be available through August 15th, 2024, by dialing (800) 770-2030 with conference ID number 6024260.